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Abstract
Lymphangiectasia (dilation of the lymphatic vessel (LV)) is pathognomonic for lymphatic filariasis. In both infected humans
and animal models of infection, lymphangiectasia is not restricted to the site of the worm nest, but is found along the
infected vessel. These observations argue that soluble products secreted by the worm could be mediating this effect by
activating the lymphatic endothelial cells (LEC) lining the vessel. We tested the ability of filarial Excretory-Secretory products
to activate LECs, but were unable to detect a direct effect of the Excretory-Secretory products on the activation of LEC as
assessed by a variety of approaches including cellular proliferation, cell surface molecule expression and cytokine and
growth factor production (although other mediators used as positive controls did induce these effects). Collectively, these
results do not support the hypothesis that Excretory-Secretory products directly activate LECs.
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Introduction
Lymphatic filariasis is a disabling disease transmitted by
mosquitoes that infects more than 120 million people throughout
the tropics. The infection is caused by filarial nematodes that reside in
the lymphatic vasculature. There is a wide spectrum of host response
phenotypes; infected individuals often appear to be asymptomatic
whereas individuals with lymphedema/elephantiasis are predomi-
nantly antigen-negative [1–6]. The factors responsible for the
progression of disease from infection to clinical lymphedema remain
undefined. Even though infected individuals appear asymptomatic,
they exhibit subclinical manifestations including lymphangiectasia or
dilated lymphatics [1–2,5]. The parasite is thought to be responsible
for alterations in the lymphatic endothelium since removal or killing
of the worms reverses the dilation [7–10]. Furthermore, lymphan-
giectasia is seen in SCID mice, arguing that the adaptive immune
response is not the only driver of this lymphatic pathology [11–12].
Lymphatic dilation is greatest near the site of the worm nest, but it is
not restricted to the site of the worm nest and is found along the
length of infected vessels suggesting that a soluble product secreted by
the worm may be mediating these effects [13–14]. These findings
support the conclusion that the presence of living adult worms and
their ES products alters LV tissue. Taken together, these observations
suggest that LECs are the prime targets of parasite-derived factors
which initiate the development of clinical pathology [15].
We and others have previously characterized the protein
constituents making up the filarial ES products released by the
worm [unpublished data, 16–18], but the biological effects of these
molecules have not been fully elucidated. Given the altered
pathology along the length of the infected vessel and intimate
relationship between the parasite and the endothelial cells lining
the LVs, worm ES products may be contributing to the
pathogenesis of disease. Therefore, we examined the biological
effects of filarial ES products on LECs. LECs were stimulated with
filarial ES products and assayed for changes in differentiation,
activation and proliferation. Changes in cell surface marker
expression profiles, the presence of phosphorylated cell signaling
molecules, gene expression and growth factor production were
used to characterize the LEC response to worm ES products.
Materials and Methods
Parasite materials and collection of ES products
Brugia malayi adult worms and microfilariae were collected from
the peritoneal cavity of infected jirds, Meriones unguiculatus, that
were obtained from the NIAID Filariasis Repository at the
University of Georgia (Athens, GA). For the collection of ES
products, 50 live adult female worms were cultured in vitro for 7
days at 37 C in 10 mL serum-free RPMI 1640 media (GIBCO)
supplemented with 2 mM L-glutamine and antibiotics (100 U/mL
penicillin and 100 mg/mL streptomycin). Supernatants were
collected and fresh medium added daily. The microfilariae were
resuspended in PBS and counted to ensure worm viability.
Supernatants containing the ES products were centrifuged at
10006 g for 10 min to remove the microfilariae and then
concentrated with a Centricon filter (Millipore, Bedford, MA) to a
volumeof ,300 mL. ESproducts werestored at4 C untilfurther use.
Prior to cell stimulations with ES products, ES products were filtered
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Co. Cork, Ireland) and used in a dose-dependent (diluted 1:10, 1:50,
1:100). All batches of ES products were tested for endotoxin activity
using the Limulus Amebocyte Lysate QCL-1000 assay (Lonza,
Walkersville, MD) and ES products were only used for cell
stimulations when endotoxin concentrations #0.1 eu/mL.
For the preparation of adult worm and microfilariae extract,
worms were stored in phosphate-buffered saline (PBS) at 280 C
until thawed. Crude worms were cut with scissors, resuspended in
3 ml PBS and ultrasonicated (Heat Systems-Ultrasonics, Inc.,
Plainview, New York; Model W-225 with standard tip) for 30 min
at 4uC. The material was centrifuged for 10 min at 15,000 g at 4 C
and the protein concentration of the supernatant was determined
by the bicinchoninic acid protein assay (Pierce, Rockford, Illinois).
Culture of ECs
Primary adult human dermal lymphatic microvascular endo-
thelial cells (HMVEC-dLy) (cat. CC-2810T25) were purchased
from Lonza Clonetics (Walkersville, MD) and maintained in
EGM-2MV Bulletkit media (cat. CC-3202) from Lonza Clonetics.
Cells were maintained according to manufacturer’s instructions
and used between passages 4 through 8. In addition, well-
characterized cell lines such as the human dermal microvascular
endothelial cell line, HMEC-1 [19], a human umbilical vein
endothelial cell line (HUVEC) and a bovine endothelial cell line
(BOVEC) were obtained from ATCC through the CDC and used
in parallel experiments. hTERT-HDLEC cells were kindly
provided by Drs. Katy Baty and David Finegold at the University
of Pittsburgh. These cells are composed of primary human dermal
microvascular endothelial cells (HDMVEC) that were transfected
with a retrovirus containing the coding region of human
telomerase reverse transcriptase (hTERT) to provide a primary
lymphatic endothelial cell line (hTERT-HDLEC) with an
extended lifespan [20]. HMEC-1, HUVEC and BOVEC cell
lines were obtained from the CDC and maintained in EBM131
media containing endothelial basal media (MCDB131; GIBCO)
supplemented with 15% FBS, 10 ng/ml epidermal growth factor,
1 mg/ml hydrocortisone, 90 mg/mL heparin, 2 mM L-glutamine
and antibiotics (100 U/mL penicillin and 100 mg/mL streptomy-
cin). For starvation experiments, cells were cultured in MCDB131
media with L-glutamine and antibiotics. hTERT-HDLECs were
maintained in the same EBM131 media as HMECs, but EndoGro
(Vec Technologies, Rensselaer, NY) was added according to
manufacturer’s instructions. Cell lines were detached from flasks
using 0.02% versene and 0.2% trypsin treatment.
Cellular proliferation
Cells were seeded into a 96-well plate and allowed to adhere
overnight. If cells were starved, cells were cultured in MCDB131
starvation media for 4 or 24 hours prior to stimulation in a
number of different media and in the presence or absence of
VEGF (1, 10 or 100 ng/mL) or ES products (diluted 1:10 to 1:250)
for 72 hours. The cell types and culture conditions used to
demonstrate EC proliferation are summarized in Table 1.
Proliferation was assayed by adding 0.5 mCi [
3H] thymidine/well
and measuring the incorporation of tritiated thymidine over the
last 8 or 16 hours of culture using a 1205 Betaplate liquid
scintillation counter (Wallac, Perkin-Elmer, Waltham, MA).
Detection of NFkB phosphorylation
LECs, HMECs or HUVECs were seeded in a 6-well plate in
EGM-2MV or EBM131 media and grown until confluent. Cells
were starved for 2.5 hours with MCDB131 media heated to 37 C.
Cells were stimulated in the warmed media for 15 min (LECs in
EGM-2MV; HUVECs in EGM131) and 30 min (HMEC in
EGM131) and lysed with 25 mL/mL 1 M Tris-HCl (pH 7.5),
50 mL/mL 20% SDS, 925 mL/mL H2O, 200 mg/mL ethylenedi-
aminetetraacetic acid (EDTA), 1 mg/mL leupeptin, 1 mg/mL
pepstatin A, 200 mg/mL Pefabloc SC (Roche, Indianapolis, IN)
and Phosphatase Inhibitor Cocktail Set II (1:100; Calbiochem, La
Jolla, CA). Lysate protein concentrations were determined by
BCA (Pierce); 2.5 mg (LEC) and 5 or 7.5 mg (HMEC) protein
per lane was separated in a 12% SDS-PAGE gel and electro-
phoretically transferred onto Immobilon-P PVDF membranes
(Millipore).
Throughout the western blotting, PBS plus 0.3% Tween was
used in each step. Following transfer, the membranes were
incubated overnight at 4 C with primary antibodies purchased
from Cell Signaling Technology (Danvers, MA) including rabbit
anti-phospho-p44/42 MAPK (1:300; cat. 4376S), rabbit anti-
phospho-pAkt (1:300; cat. 4056), rabbit anti-phospho-pNFkB
p105 (1:300; cat. 4884) or rabbit anti-p44/42 MAPK (1:300; cat.
9102), rabbit anti-Akt (1:300; cat. 9272), rabbit anti-NFkB p105/
p50 (1:300; cat. 3035) or mouse anti-b-tubulin (1:4000; cat.
T6074; Sigma). The membranes were washed and incubated for
1 hour with HRP-conjugated goat anti-rabbit IgG antibody
(1:1000; cat. 7074; Cell Signaling Technology) or HRP-conjugated
goat anti-mouse IgG antibody (1:1000; cat. 12–349; Millipore), as
appropriate. After a final wash, the bound conjugates were
visualized by 3,39-diaminobenzidine (Sigma) as the chromagenic
substrate.
Cytokine and growth factor production
LECs were plated in a 6-well plate at 3610
5 cells per well in
1.5 mL EGM-2MV media and the monolayer was grown until
confluent. LECs were then stimulated with or without 100 ng/mL
LPS, 10 ng/mL TNFa or ES diluted at 1:10 for 72 hours. Cell
culture supernatants were collected and stored at 280 C until
further use. For parallel experiments examining the effects of
filarial crude worm and microfilariae extracts, 3610
5 LECs were
Table 1. In vitro cell culture conditions for EC proliferation experiments.
Cell type
Media used for 72 hour
stimulation Cell No. (range) Serum (range) Starvation time in MCDB131 (serum-free)
BOVEC EBM131 or MCDB131 4610
3–2610
4 0 or 15% FBS 24 hours
HMEC EBM131 or MCDB131 4610
3–2610
4 0 or 15% FBS No starvation; 4 or 24 hour starvation
hTERT-HDLEC EBM131 + EndoGro 1610
4 15% FBS No starvation
LEC MCDB131 or EGM-2MV 2610
3–5610
4 1.25–10% and 15% FBS
1.25–10% NHS
No starvation; 4 or 24 hour starvation
doi:10.1371/journal.pone.0022282.t001
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stimulated with or without Brugia ES products (1:10), Brugia adult
worm extract (10 mg/mL), Brugia microfilarial extract (25 mg/mL
or 10 mg/mL) for 24 hrs and supernatants were collected.
Supernatants were analyzed for IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-12p70, IL-13, IFNc, TNFa and VEGF-A by luminex
technology using the Bio-Plex Pro multiplex suspension array
system (Bio-Rad, Hercules, CA) according to the manufacturer’s
instructions. Data were analyzed by the Bio-Plex Manager
software version 4.1.1 and concentrations were calculated based
on a standard curve derived from recombinant cytokine standards.
If the cytokine level in the sample was lower than the lowest value
on the standard curve, which occurred in multiple stimulations,
the lowest value of the standard curve was reported for that data
point.
For the production of VEGF-C and VEGF-D, LECs were plated
in a 24-well plate at 2.5610
4 cells per well in 500 mLE G M - 2 M V
media and allowed to adhere for 24 hours at which point the
monolayer was also confluent. LECs were starved for 24 hours in
MCDB131 media and then stimulated in 1.5 mL EGM-2MV media
with or without 10 ng/mL TNFa or ES diluted at 1:10 for 72 hrs.
Cell culture supernatants were collected and stored at 280 C until
further use. VEGF-C and VEGF-D production were analyzed by the
Quantikine Immunoassay kits (R&D, Minneapolis, MN) as directed
by the manufacturer. All cytokine and growth factor production
experiments were carried out in triplicate.
Flow cytometry
LECs, HMECs or HUVECs were grown to confluence in their
appropriate media and either starved for 24 hours in MCDB131
or directly stimulated in the appropriate media with or without
100 ng/mL LPS, 10 ng/mL TNFa or ES (diluted at 1:10 and
1:50) for 24 hours. Cells were removed from the flask by
trypsinization and stained for 30 min on ice in the dark according
to manufacturers’ directions using unconjugated rabbit anti-
human VEGFR-3 (cat. 102-PA18AG; ReliaTech, Braunschweig,
Germany), mouse anti-human podoplanin (cat. 101-M40; Relia-
Tech) and rabbit anti-human LYVE-1 (cat. 102-PA50S; Relia-
Tech) primary antibodies and followed by secondary staining
using FITC-labeled goat anti-rabbit (cat. 554020; BD Pharmin-
gen) and PE-labeled goat anti-mouse antibodies (cat. 550589; BD
Pharmingen). Cells were also stained using primary antibodies
purchased from BD Pharmingen including conjugated PE-Cy5-
labeled anti-human ICAM-1 (cat. 555512), FITC-labeled anti-
human VCAM-1 (cat. 551146) and PE-Cy5-labeled anti-human
E-selectin (cat. 550040). Cell events were acquired and analyzed
on a BD FACScan flow cytometer (BD Biosciences, San Jose, CA).
Results
To model the intimate interaction between worm ES products
and the LECs in filarial infection, an in vitro model system was
established in which LECs were exposed to filarial ES products
released by the parasite. Patients with active infection exhibit
lymphangiectasia whereby LVs are dilated, but the mechanism
causing this alteration is not known. The diameter of an infected
LV is increased and this dilation could be a result of an increase in
the number of LECs lining the lymphatic lumen, so we measured
the proliferation of LECs stimulated with filarial ES products. To
test this, decreasing concentrations (1:10 to 1:100) of ES products
were added to LECs as well as the hTERT-HDLEC and HMEC-
1 cell lines in vitro for various time periods and proliferation was
compared to cells cultured in media alone. Under various
starvation conditions and in the presence of a range of natural
human or fetal bovine serum concentrations (1.25–10%) in
multiple EC media (including EGM-2MV, EBM131 and basal
MCDB131), we were not able to detect reproducible LEC
proliferation in response to worm ES products; a representative
experiment using LECs is shown in Figure 1.
When we did not detect increased rates of EC proliferation in
response to worm ES products, we examined the ECs for earlier
activation events such as the phosphorylation of cell signaling
molecules. ECs including LECs, HMECs and HUVECs were
stimulated with or without ES (1:10) or TNFa and the
phosphorylation of NFkB, Akt and MAPK ERK1/2 was
compared to cells cultured in media alone at the same time
points. In pilot experiments, we defined optimal time points for
detection of the phosphorylated molecules in response to TNFa
(data not shown). We were not able to detect reproducible
phosphorylation of either NFkB or Akt in response to worm ES
products. We did detect the phosphorylation of the MAPK
ERK1/2 p44/42 subunit in response to worm ES products, but
this was a transient response that was not associated with any
downstream events in our analyses.
Cytokine and growth factor production by LECs in response to
worm ES products as well as LPS and/or TNFa were also assessed
to identify any downstream cellular activation events that might be
associated with the phosphorylation of cell signaling molecules.
After 72 hours of culture, IL-1b, IL-6, IFNc and TNFa
production were only detected in supernatants from LECs
stimulated with LPS but not ES or TNFa; IL-8 production was
similar for all experimental parameters (Fig. 2). IL-2, IL-12, and
IL-13 were not induced by ES, LPS or TNFa and IL-4, IL-5 and
IL-10 production were below the detection limits of the luminex
assay regardless of stimulus (data not shown). It should be noted
that LECs stimulated with microfilariae crude extract significantly
stimulated the production of GM-CSF and IL-2, suggesting that
LECs can respond to filarial-specific products extracted from dead
parasites (Fig. S1). For growth factor production, similar levels of
Figure 1. Proliferation of LECs in response to filarial ES
products. 5610
4 LECs were plated in a 96 well plate in EBM-2MV
and allowed to adhere for 24 hours. Cells were starved for 24 hours in
MCBD media and then stimulated with or without VEGF (10 ng/mL) or a
dilution series of filarial ES products from 1:10 to 1:100 in MCDB media
containing 5% NHS for 72 hours. Thymidine incorporation was
measured. Data seen here is one representative LEC proliferation
experiment. Various cell lines, cell numbers, starvation conditions,
media types and serum types were utilized for optimization of this
assay but we never detected reproducible proliferation rates in
response to ES products.
doi:10.1371/journal.pone.0022282.g001
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unstimulated LEC supernatants after 72 hours (Fig. 3) and VEGF
production was below the limits of detection by the luminex assay
(data not shown).
Endothelial cells were also examined for changes in the
expression of cell surface molecules in response to filarial ES
products. ICAM-1 and VCAM-1 are adhesion molecules known
to be expressed on the surface of blood vascular endothelial cells
and up-regulated in response to inflammatory stimuli; therefore,
we measured the expression of ICAM-1 and VCAM-1 on LECs as
well as HMECs and HUVECs that were stimulated with worm ES
products for 24 hours. We did not detect an up-regulation of
ICAM-1 and VCAM-1expression in any of the ECs tested in
response to worm ES but we did detect an up-regulation of these
adhesion molecules in response to TNFa (Fig. 4).
We also analyzed LECs for changes in LEC-specific surface
marker expression by flow cytometry. We did not detect and up-
regulation of LYVE-1, podoplanin or VEGFR-3 surface expres-
sion on LECs that were stimulated with worm ES products or
TNFa compared with the LECs cultured in media alone (data not
shown).
Discussion
The association of lymphangiectasia with the presence of active
filarial infection argues that, soluble parasite factors may be
mediating the effect in vivo. We originally hypothesized that the ES
products of the worms were activating the lymphatic endothelium;
however, we were not able to detect a direct effect of the ES
products on the activation of LECs as summarized in Table 2. We
Figure 2. Cytokine production by LECs in response to filarial ES products. 3610
5 LECs were plated in EGM-2MV media and allowed to come
to confluence. Cells were then stimulated in EGM-2MV media with or without ES (1:10), LPS (100 ng/mL) or TNFa (10 ng/mL) for 72 hrs and
supernatants were harvested and assessed for cytokine production including IL-1b (A), TNFa (B), IL-8 (C), IL-6 (D) and IFNc (E) by luminex bead
technology. Experiments were completed in triplicate and this figure includes representative data from one experiment.
doi:10.1371/journal.pone.0022282.g002
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4 LECs were plated in EGM-2MV media and allowed to
adhere for 24 hours. Cells were then starved for 24 hours in MCDB-131 media prior to stimulation for 24 hours in EGM-2MV media with or without ES
(1:10) or TNFa (10 ng/mL). Supernatants were harvested and assessed for growth factor production including VEGF-C (A) and VEGF-D (B) by ELISA.
Experiments were completed in triplicate and this figure includes representative data from one experiment.
doi:10.1371/journal.pone.0022282.g003
Figure 4. Surface expression of adhesion molecules in response to worm ES products. LECs were grown to confluence in EGM-2MV media
then cells were stimulated for 24 hours in EGM-2MV media with or without ES (1:10) or TNFa (10 ng/mL). LECs were harvested and subjected to flow
cytometry analysis for the expression of ICAM-1 or VCAM-1. This figure includes representative data from one experiment.
doi:10.1371/journal.pone.0022282.g004
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in the rate of LEC proliferation, but we did not see increased
proliferation of these cells in repeated assays. In addition, the
LECs did not appear to be stimulated by ES products as assessed
by expression of cell surface molecules or production of growth
factors or cytokines. The positive controls in these assays induced
the expected responses, so the cells were viable and functional;
however, the filarial ES products did not induce detectable
responses by LECs.
Some authors have proposed that lymphatic filarial parasites
induce endothelial and connective tissue proliferation in vivo which
in turn causes the thickening of the endothelium [21–22]. The
cuboidal ECs seen in B. malayi-infected nude mice suggest that a
multiplication of LECs may also contribute to lymphangiectasia
[23]. However, this phenomenon could not be reproduced in vitro
with human umbilical vein endothelial cells [15]. We repeated
these in vitro experiments with LECs, but we were still not able to
detect an increase in EC proliferation in response to worm ES
products under the culture conditions that we employed. In these
experiments, we used ES products from adult female worms
because of their greater abundance compared to ES products of
male worms. We should also note that the ES products used to
stimulate LECs do contain ES products of microfilariae, as this
parasite stage is also released by the female worm in vitro at the
same time that the female worm secretes ES products. We did not
attempt to separate the adult female and microfilarial ES products
as both may be found in the infected lymphatic vessels potentially
inducing lymphatic dilation. We reasoned that ES products from
both stages would be best to reproduce the biological environment
in vivo. In preliminary experiments, we also attempted to co-culture
living adult worms with LEC monolayers, but the active
movement of the living adult worms disrupted the LEC
monolayer, preventing our efforts to address the direct effect of
the living parasites on LEC function.
In our hands, we were not able to demonstrate reproducible
LEC proliferation in response to the positive control VEGF. The
lack of a robust in vitro proliferation response to VEGF is not
uncommon and many responses only exhibit ,50% increase over
ECs stimulated in media alone [24–26]. VEGF did not induce a
significant increase in the proliferation of LECs even at lower
seeding numbers, other serum concentrations or other stimulation
times suggesting VEGF may not be the best positive control for in
vitro proliferation studies using LECs, but may be better suited for
vascular ECs. The lack of proliferation seen in the HMVEC-dLy
cells upon stimulation with VEGF may result from the commercial
optimization of culture conditions for these cells with VEGF.
According to the manufacturer’s instructions, these primary LECs
require VEGF for routine culture so the ability of VEGF to induce
LEC proliferation may be diminished.
In general and in our cultures, the lack of LEC proliferation is
most likely related to the stringency of the culture conditions
required for cell growth. However, Bennuru and Nutman
demonstrated microfilariae-induced LEC differentiation as mea-
sured by tubule formation, suggesting that further investigation is
needed to address the potential role of microfilariae in altering
lymphatic pathology [27]. In parallel experiments, microfilariae
crude worm extract stimulated the production of various
lymphangiogenic and immunologic mediators such as GM-CSF
and IL-2 by LECs confirming the ability of LECs to respond to
filarial-specific products but these mediators were not produced at
elevated levels by LECs exposed to filarial ES products (Fig. S1).
This suggests that LECs exhibit differential responses to individual
parasite stages or products. Furthermore, given that ES products
contain products from both adult worms as well as microfilariae,
and there was not an increase in cytokine production by LECs in
response to ES products, these data also demonstrate a differential
response between microfilarial ES products and microfilarial crude
worm extract. Taken together, these data suggest that EC
proliferation under these culture conditions does not result from
direct exposure to adult female worm and microfilariae ES
products; however, EC proliferation may require unidentified
culture conditions, other parasite stages or involve other factors,
such as accessory host cells or host-derived products.
It should be noted that subsequent experiments in our lab
revealed that filarial ES products stimulated human peripheral
blood mononuclear cells (PBMCs), and specifically monocytes, to
produce lymphangiogenic mediators arguing that the lack of
measurable effects on LECs in response to worm ES products is
not a result of protein concentration (unpublished data, Weinkopff
et. al). Lymphangiogenic mediators produced by PBMCs in
response to stimulation with filarial ES products were able to alter
the behavior of LECs in vitro and in vivo as measured by tubule
formation suggesting that LECs are indirectly activated by filarial
ES products through the production of lymphangiogenic media-
tors from PBMCs (unpublished data, Weinkopff et. al). The
involvement of host-derived products mediating lymphangiectasia
is supported by the observation that serum from infected
individuals can induce LEC proliferation [27].
Even though we did not identify a reproducible activation event
induced by worm ES, we did demonstrate robust responses of
LECs to the positive controls, TNFa and LPS, in multiple assays.
Here, we report that both TNFa and LPS stimulate LECs to
activate cell signaling events, up-regulate cell surface adhesion
molecules and induce growth factor and cytokine production.
Table 2. Incubation of LECs with Brugia ES fails to induce cellular activation as measured by a variety of parameters.
Activation Event Measurement Cell Type
Proliferation Thymidine incorporation HMEC, hTERT-hdLEC
c, BOVEC or LEC
Cell signaling Western blot for: MAPK ERK1/2, Akt, NFkB HMEC, HUVEC, LEC
d
Cell surface molecule expression
a,b Flow cytometry for: ICAM-1, VCAM-1, E-selectin, VEGFR-3, LYVE-1,
podoplanin or Prox-1
HMEC, HUVEC (VCAM-1 only) or LEC
Growth factor production
a,b ELISA for: VEGF (VEGF-A), VEGF-C or VEGF-D HMEC or LEC
Cytokine production
a,b Bioplex for: IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p, IL-13, IFNc,T N F a LEC
aLPS (100 ng/ml) used as a positive control;
bTNFa (10 ng/mL) used as a positive control;
chTERT-hdLEC [20];
dPhosphorylation of MAPK observed in LECs but not other cell type.
doi:10.1371/journal.pone.0022282.t002
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VCAM-1 expression on LECs by flow cytometry [28] and TNFa
has also been reported to enhance ICAM-1 and VCAM-1
transcript levels [29]. In our hands LPS (100 ng/mL) induced
the production of IL-1b, IL-6 and TNFa by LECs compared to
unstimulated LECs (Fig. 2) and similar results were reported by
Pegu et al. [29]. Collectively, these data argue that even though we
did not detect an ES-induced activation event in LECs, our cells
were viable and we had established the appropriate positive
controls to induce and detect optimum responses.
In conclusion, we were not able to demonstrate a direct
activation of LECs by filarial ES products. The lack of evidence for
a direct activation event may be explained by the limitations of an
in vitro culture model system. Given the longevity of filarial
infections, worms can exist in LVs for years where they release
soluble factors that may gradually alter the lymphatic endotheli-
um. In our in vitro cultures, we only carried out the LEC-
stimulations with ES products for 72 hours; this may not be
enough time to recreate the effects seen in infected vessels. The
negative results may also suggest that a more complicated network
is established between the parasite and the host and the LECs may
be indirectly activated through a host accessory cell or its
mediators.
Supporting Information
Figure S1 Evidence for the production of immunologic
mediators by LECs. 3610
5 LECs were plated in EBM and
stimulated with or without Brugia ES products (1:10), Brugia adult
worm extract (10 mg/mL), Brugia microfilarial extract (25 mg/mL
or 10 mg/mL) for 24 hrs and supernatants were harvested and
assessed for cytokine production including GM-CSF and IL-2 by
luminex bead technology. Experiments were completed in
triplicate and this figure includes data from one experiment.
(TIFF)
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